Precision Public Health Applications of Liquid Biopsy Genomics for Colorectal Cancer: Evidence, Equity, and Implementation Challenges

Kintuza Lumwako Tebulo

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Colorectal cancer (CRC) remains a leading cause of cancer morbidity and mortality worldwide, with early detection critical to improving outcomes. Liquid biopsy genomics offers a minimally invasive approach to detect tumor-derived analytes in biofluids, providing insights into tumor burden, genomic alterations, and treatment response. Precision public health applications of liquid biopsy enable population-level risk stratification, integration of genomic, clinical, and sociodemographic data, and targeted interventions for early-stage CRC detection. Evidence indicates that liquid biopsy can enhance screening accessibility, particularly in underserved populations, while supporting real-time monitoring of therapeutic response and disease recurrence. However, challenges persist in implementation, including data integration, health system logistics, workforce capacity, regulatory frameworks, and equity considerations. Addressing these barriers is essential for translating liquid biopsy genomics into actionable population-level CRC interventions.

Keywords: Colorectal Cancer, Liquid Biopsy, Precision Public Health, Genomics and Health Equity.

CITE AS: Kintuza Lumwako Tebulo. (2026). Precision Public Health Applications of Liquid Biopsy Genomics for Colorectal Cancer: Evidence, Equity, and Implementation Challenges. RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 5(1): 70-73. https://doi.org/10.59298/RIJPP/2026/517073